UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence”

Advances in therapy, 2021-06, Vol.38 (6), p.3483-3486

2021

Volltextzugriff (PDF)

Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study

Future oncology (London, England), 2019-01, Vol.15 (3), p.297-303

2019

Volltextzugriff (PDF)

Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit

Oncology and therapy, 2022-12, Vol.10 (2), p.351-361

2022

Volltextzugriff (PDF)

Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy

Journal of comparative effectiveness research, 2018-12, Vol.7 (12), p.1161-1170

2018

Volltextzugriff (PDF)

Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting

Journal of comparative effectiveness research, 2019-07, Vol.8 (9), p.657-670

2019

Volltextzugriff (PDF)

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial

Cancer management and research, 2017-01, Vol.9, p.179-187

2017

Volltextzugriff (PDF)

Ex ante budget impact analysis (BIA) of PD-1 inhibitor toripalimab plus gemcitabine-cisplatin (T+GC) versus a simulated pembrolizumab regimen in first line (1L) treatment of recurrent or metastatic nasopharyngeal cancer (rmNPC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18024-e18024

2022

Volltextzugriff (PDF)

Efficacy of Low-Dose Dopamine in Preventing Amphotericin B Nephrotoxicity in Bone Marrow Transplant Patients and Leukemia Patients

Antimicrobial Agents and Chemotherapy, 1998-12, Vol.42 (12), p.3103-3106

1998

Volltextzugriff (PDF)

Real-world data comparison of time to next treatment for patients with HER2 positive metastatic breast cancer treated in the second line of therapy with fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl)

2024

Volltextzugriff (PDF)

Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16258-e16258

2023

Volltextzugriff (PDF)

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.666-666

2023

Volltextzugriff (PDF)

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4534-4534

2023

Volltextzugriff (PDF)

Effect of APF530 on health-related quality of life (QOL) and other chemotherapy-induced nausea and vomiting (CINV) end points: Phase III MAGIC trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e21666-e21666

2016

Volltextzugriff (PDF)

Phase III MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (Fos) + dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e21700-e21700

2016

Volltextzugriff (PDF)

Evaluation of chemotherapy-induced nausea and vomiting (CINV) events and associated resource utilization for CINV in patients(pts) treated with highly emetogenic chemotherapy (HEC) and carboplatin (Carbo) and palonosetron (palo)-based anti-emetic regimens

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e21649-e21649

2016

Volltextzugriff (PDF)

Real-world effectiveness of palonosetron within a three-drug regimen to prevent chemotherapy induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e18231-e18231

2016

Volltextzugriff (PDF)

APF530 for nausea and vomiting prevention following cisplatin: phase 3 MAGIC trial analysis

The Journal of community and supportive oncology, 2017-03, Vol.15 (2), p.82-88

2017

Volltextzugriff (PDF)

Effect of postremission chemotherapy before human leukocyte antigen–identical sibling transplantation for acute myelogenous leukemia in first complete remission

Blood, 2000-08, Vol.96 (4), p.1254-1258

2000

Volltextzugriff (PDF)

Re: Severe Interaction Between Methotrexate and a Macrolide-like Antibiotic

JNCI : Journal of the National Cancer Institute, 1995-11, Vol.87 (21), p.1641-1642

1995

Volltextzugriff (PDF)

A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation

Blood, 2000-07, Vol.96 (1), p.80-85

2000

Volltextzugriff (PDF)

A Pilot Study of Prophylactic Aerosolized Amphotericin B In Patients at Risk for Prolonged Neutropenia

Leukemia & lymphoma, 1992, Vol.8 (3), p.229-233

1992

Volltextzugriff (PDF)

A Phase I Study of Cloretazine® and Temozolomide in Patients with Hematologic Malignancies

Blood, 2006-11, Vol.108 (11), p.1971-1971

2006

Volltextzugriff (PDF)

Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients

Transplantation, 1996-04, Vol.61 (8), p.1268

1996

Volltextzugriff (PDF)

Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem‐cell glycoprotein CD34 (My 10)

British journal of haematology, 1990-11, Vol.76 (3), p.340-347

1990

Volltextzugriff (PDF)

High-dose chemotherapy with autologous stem cell rescue in the outpatient setting

Oncology (Williston Park, N.Y.), 2000-02, Vol.14 (2), p.171

2000

Volltextzugriff (PDF)

1 – 25 von 240

Suche als RSS-Feed

Aktive Filter

ThemaChild

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(217)
Mit Volltextzugriff
(188)

Publikationsform

Sprache

Englisch
(239)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence”

Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study

Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit

Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy

Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial

Ex ante budget impact analysis (BIA) of PD-1 inhibitor toripalimab plus gemcitabine-cisplatin (T+GC) versus a simulated pembrolizumab regimen in first line (1L) treatment of recurrent or metastatic nasopharyngeal cancer (rmNPC)

Efficacy of Low-Dose Dopamine in Preventing Amphotericin B Nephrotoxicity in Bone Marrow Transplant Patients and Leukemia Patients

Real-world data comparison of time to next treatment for patients with HER2 positive metastatic breast cancer treated in the second line of therapy with fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine

Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC)

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC)

Effect of APF530 on health-related quality of life (QOL) and other chemotherapy-induced nausea and vomiting (CINV) end points: Phase III MAGIC trial

Phase III MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (Fos) + dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender

Evaluation of chemotherapy-induced nausea and vomiting (CINV) events and associated resource utilization for CINV in patients(pts) treated with highly emetogenic chemotherapy (HEC) and carboplatin (Carbo) and palonosetron (palo)-based anti-emetic regimens

Real-world effectiveness of palonosetron within a three-drug regimen to prevent chemotherapy induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC)

APF530 for nausea and vomiting prevention following cisplatin: phase 3 MAGIC trial analysis

Effect of postremission chemotherapy before human leukocyte antigen–identical sibling transplantation for acute myelogenous leukemia in first complete remission

Re: Severe Interaction Between Methotrexate and a Macrolide-like Antibiotic

A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation

A Pilot Study of Prophylactic Aerosolized Amphotericin B In Patients at Risk for Prolonged Neutropenia

A Phase I Study of Cloretazine® and Temozolomide in Patients with Hematologic Malignancies

Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients

Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem‐cell glycoprotein CD34 (My 10)

High-dose chemotherapy with autologous stem cell rescue in the outpatient setting

Aktive Filter

Suchergebnisse filtern